UbiVac Overview

  • Founded
  • 2005
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $1.95M
Latest Deal Amount
  • Investors
  • 2

UbiVac General Information


Developer of therapeutic vaccines intended to combat cancer and infectious diseases. The company's DPV-001 is a complex vaccine/combination immunotherapy which induces and/or boosts the immune response in every patient who receives it, enabling patients to fight cancer and increase immunity.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 18183 South West Boones Ferry Road
  • Portland, OR 97224
  • United States
+1 (503) 000-0000

UbiVac Timeline

Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

UbiVac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Angel (individual) 26-Apr-2019 $1.95M 00.000 Completed Startup
6. Angel (individual) 24-May-2018 00000 00000 Completed Startup
5. Grant 18-Aug-2016 00000 Completed Startup
4. Grant 31-Aug-2014 00000 Completed Startup
3. Grant 01-Jan-2013 00000 Completed Startup
2. Grant 01-Jan-2009 $3.46M Completed Startup
1. Grant 01-Jan-2006 $152K Completed Startup
To view UbiVac’s complete valuation and funding history, request access »

UbiVac Executive Team (3)

Name Title Board Seat Contact Info
Bernard Fox Ph.D Co-Founder, President & Chief Executive Officer
Bernard Fox III Chief Operating Officer
Hong-Ming Hu Ph.D Co-Founder & Chief Scientific Officer
To view UbiVac’s complete executive team members history, request access »

UbiVac Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view UbiVac’s complete investors history, request access »